Compass Therapeutics, Inc. (CMPX)
0.8967
+0.02
(+2.01%)
USD |
NASDAQ |
Oct 15, 16:00
0.89
-0.01
(-0.75%)
After-Hours: 20:00
Compass Therapeutics Research and Development Expense (Quarterly) : 19.56M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.56M |
| March 31, 2026 | 13.38M |
| December 31, 2025 | 13.66M |
| September 30, 2025 | 12.81M |
| June 30, 2025 | 16.32M |
| March 31, 2025 | 12.91M |
| December 31, 2024 | 12.89M |
| September 30, 2024 | 8.469M |
| June 30, 2024 | 11.02M |
| March 31, 2024 | 9.368M |
| December 31, 2023 | 12.26M |
| September 30, 2023 | 8.667M |
| June 30, 2023 | 10.04M |
| March 31, 2023 | 6.444M |
| December 31, 2022 | 9.733M |
| Date | Value |
|---|---|
| September 30, 2022 | 9.589M |
| June 30, 2022 | 5.642M |
| March 31, 2022 | 4.25M |
| December 31, 2021 | 9.45M |
| September 30, 2021 | 3.154M |
| June 30, 2021 | 2.905M |
| March 31, 2021 | 4.704M |
| December 31, 2020 | 4.406M |
| September 30, 2020 | 3.67M |
| June 30, 2020 | 2.985M |
| March 31, 2020 | 3.571M |
| December 31, 2019 | 3.303M |
| September 30, 2019 | 5.979M |
| June 30, 2019 | 5.389M |
| March 31, 2019 | 7.243M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | 115.75M |
| Capricor Therapeutics, Inc. | 28.57M |
| Ardelyx, Inc. | 25.50M |
| Biomea Fusion, Inc. | 9.142M |
| ARS Pharmaceuticals, Inc. | 4.698M |